Physician profile
Seth M Pollack
NPI 1528234143
$154,773.10
in general payments reported to CMS, 2019-2025
20 companies · $44K in 2025
The $44K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2021: $17K · 2022: $17K · 2023: $13K · 2024: $53K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $28K · Travel and Lodging: $4,853 · Honoraria: $3,510 · Food and Beverage: $3,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,250.50 |
| Consulting Fee | $28,217.50 |
| Travel and Lodging | $4,852.82 |
| Honoraria | $3,510.00 |
| Food and Beverage | $3,011.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $57,253.08 | 2021-2025 | Qinlock, Romvimza, Vimseltinib |
| Springworks Therapeutics, INC. | $45,762.07 | 2024-2025 | Ogsiveo |
| Daiichi Sankyo INC. | $18,115.94 | 2019-2025 | Turalio, Vanflyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,992.00 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $6,562.24 | 2024-2025 | Tazverik |
| Emd Serono, INC. | $4,275.00 | 2025 | |
| Glaxosmithkline, LLC. | $3,900.00 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,931.93 | 2019-2023 | |
| Aadi Bioscience, INC. | $2,755.77 | 2022-2024 | Fyarro |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Janssen Biotech, INC. | $100.07 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.